<DOC>
	<DOCNO>NCT02961660</DOCNO>
	<brief_summary>The main purpose study evaluate pharmacokinetics ( PK ) single oral dose odalasvir ( ODV ) participant severe renal impairment compare PK match participant normal renal function .</brief_summary>
	<brief_title>A Study Evaluate Effect Severe Renal Impairment Single-dose Pharmacokinetics Odalasvir</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Cohorts 1 2 : Participant must body mass index ( BMI ; weight kilogram ( kg ) divide square height meter ) 18 36 kilogram per meter square ( kg/m^2 ) , extremes include , body weight less 50.0 kg Participant must willing able adhere prohibition restriction specify protocol Male Participant must agree donate sperm enrollment ( Day 1 ) study least 30 day receive study drug Female Participant , except postmenopausal , must negative serum ( beta human chorionic gonadotropin [ beta hCG ] ) pregnancy test screen negative highly sensitive urine pregnancy test Day 1 Cohort 1 : Participant must severe renal impairment require dialysis , define estimate glomerular filtration rate ( eGFR ) less ( &lt; ) 30 milliLiter per minute ( mL/min ) /1.73 m^2 Participant must stable renal function significant change renal function evidence ( mean ) screen serum creatinine value within +/25 percent ( % ) determination obtain least 3 month prior screen , expect remain stable study , plan initiate dialysis study period Participant must otherwise healthy except renal impairment underlie disease state mild comorbidities participant must medically stable basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) , clinical laboratory test perform screen . If abnormality result outside normal reference range , participant may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . This determination must record participant 's source document initial investigator Cohort 2 : Participant must healthy basis physical examination , medical history , vital sign , 12lead ECG , clinical laboratory test perform screen Participant must eGFR great equal ( &gt; = ) 90 mL/min/1.73 m^2 Cohorts 1 2 : Participant history illness ( unrelated renal impairment underlie disease , appropriate ) , opinion investigator , might confound result study pose additional risk administer study drug participant . This may include limited history relevant drug food allergy , history cardiovascular central nervous system disease , history presence clinically significant pathology , chronic skin disease , history mental disease Participant vegetarian diet take creatine supplement , nonstandard muscle mass , example amputation , malnutrition , muscle wasting , extremely muscular ( body building ) Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( anti HCV ) positive , clinically active liver disease , test positive HBsAg antiHCV screen Participant history human immunodeficiency virus ( HIV ) antibody positive , test positive HIV screening Participant smoke 10 cigarette 2 cigar 2 pipe per day within 3 month screen end study Participant woman pregnant , breastfeeding , plan become pregnant signing informed consent form ( ICF ) onwards 30 day study drug administration Participant man plan father child enrol study ( Day 1 ) 30 day study drug administration Cohort 1 : Participant require dialysis Participant imminent renal replacement therapy ( , study period )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>